12:00 AM
 | 
Aug 06, 2012
 |  BC Week In Review  |  Company News  |  Deals

Amgen, Takeda deal

Amgen and Takeda restructured a 2008 deal under which the parties and Takeda's Millennium Pharmaceuticals Inc. subsidiary were co-developing worldwide and sharing profits for Amgen's motesanib. Under the restructured deal, Takeda now has exclusive, worldwide rights to develop and commercialize motesanib. Takeda now has exclusive rights to profits within Japan, and Amgen and Takeda will share profits...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >